Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India

BACKGROUND: Plerixafor is used for patients at risk of Stem cell mobilization failure based on clinical factors or low peripheral blood CD34 count. It is also added upfront to any mobilization irrespective of risk factor, but the cost-effectiveness of the approach is an issue. Data on plerixafor in...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Soumya, Kayal, Smita, Dubashi, Biswajit, Basavarajegowda, Abhishekh, Pasupala, Nanda Kishore, Kulkarni, Rajendra, Dhanraju, Krishnappa, Pani, Chinmaya Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528564/
https://www.ncbi.nlm.nih.gov/pubmed/36199417
http://dx.doi.org/10.4103/ajts.ajts_106_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528564/
https://www.ncbi.nlm.nih.gov/pubmed/36199417
http://dx.doi.org/10.4103/ajts.ajts_106_21

Ejemplares similares